证券代码：833819 证券简称：颖泰生物 公告编号：2025-010 北京颖泰嘉和生物科技股份有限公司 独立董事述职报告（潘永昕） 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 本人潘永昕作为公司独立董事，在任职期间严格按照《公司法》 《证券法》《上市公司独立董事管理办法》《北京证券交易所股票上市 规则（试行）》《北京证券交易所上市公司持续监管指引第 1 号——独 立董事》以及《公司章程》《独立董事工作制度》等法律法规及规范 性文件的规定，认真、勤勉、谨慎地履行独立董事职责，行使公司所 赋予独立董事的权利，充分发挥独立董事的作用，切实维护了公司整 体利益和全体股东尤其是中小股东的合法权益。履职过程中，公司积 极支持和配合本人完成工作，未有妨碍独立董事独立性的情况发生。 公司于 2024 年 12 月 9 日召开第四届董事会第七次独立董事专 门会议、2024 年 12 月 10 日召开第四届董事会第九次会议、2024 年 12 月 26 日召开 2024 年第一次临时股东大会，审议通过《关于增补 潘永 ...

证券代码：833819 证券简称：颖泰生物 公告编号：2025-008 北京颖泰嘉和生物科技股份有限公司 独立董事述职报告（万勇） 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 本人万勇作为公司独立董事，在任职期间严格按照《公司法》《证 券法》《上市公司独立董事管理办法》《北京证券交易所股票上市规则 （试行）》《北京证券交易所上市公司持续监管指引第 1 号——独立董 事》以及《公司章程》《独立董事工作制度》等法律法规及规范性文 件的规定，认真、勤勉、谨慎地履行独立董事职责，行使公司所赋予 独立董事的权利，充分发挥独立董事的作用，切实维护了公司整体利 益和全体股东尤其是中小股东的合法权益。履职过程中，公司积极支 持和配合本人完成工作，未有妨碍独立董事独立性的情况发生。现将 2024 年度本人履行职责情况报告如下： 一、 会议出席情况 2024 年度，本人参加了公司召开的董事会、股东大会、独立董事 专门会议以及董事会审计委员会，认真行使独立董事职责，根据相关 法律和制度的规定，认真审议所有议案，并审慎行使 ...

证券代码：833819 证券简称：颖泰生物 公告编号：2025-007 北京颖泰嘉和生物科技股份有限公司 独立董事述职报告（李钟华-已离任） 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 本人李钟华作为公司独立董事，在任职期间严格按照《公司法》 《证券法》《上市公司独立董事管理办法》《北京证券交易所股票上市 规则（试行）》《北京证券交易所上市公司持续监管指引第 1 号——独 立董事》以及《公司章程》《独立董事工作制度》等法律法规及规范 性文件的规定，认真、勤勉、谨慎地履行独立董事职责，行使公司所 赋予独立董事的权利，充分发挥独立董事的作用，切实维护了公司整 体利益和全体股东尤其是中小股东的合法权益。 本人因个人原因已于 2024 年 11 月 29 日申请辞去公司独立董事 职务，2024 年 12 月 26 日公司召开股东大会选举产生新任独立董事 起辞职生效。 现将本人 2024 年度任职期间履行职责情况报告如下： 一、 会议出席情况 2024 年度，本人参加了公司召开的董事会、股东大会以及独立董 事 ...

证券代码：833819 证券简称：颖泰生物 公告编号：2025-009 北京颖泰嘉和生物科技股份有限公司 独立董事述职报告（赵强） 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 本人赵强作为公司独立董事，在任职期间严格按照《公司法》《证 券法》《上市公司独立董事管理办法》《北京证券交易所股票上市规则 （试行）》《北京证券交易所上市公司持续监管指引第 1 号——独立董 事》以及《公司章程》《独立董事工作制度》等法律法规及规范性文 件的规定，认真、勤勉、谨慎地履行独立董事职责，行使公司所赋予 独立董事的权利，充分发挥独立董事的作用，切实维护了公司整体利 益和全体股东尤其是中小股东的合法权益。履职过程中，公司积极支 持和配合本人完成工作，未有妨碍独立董事独立性的情况发生。现将 2024 年度本人履行职责情况报告如下： | 独立董事姓名 | 出席独立董事专门会议次数 | 出席独立董事专门会议方式 | | --- | --- | --- | | 赵强 | 5 | 通讯、现场 | 2024 年度共召开 5 次独立 ...

Financial Performance - Net profit attributable to shareholders for Q1 2025 was ¥2,348,404.41, representing a significant increase of 107.89% year-over-year [8]. - Operating revenue for the first quarter of 2025 reached ¥1,387,275,846.94, reflecting a growth of 0.96% compared to the same period last year [8]. - The company reported a net profit of ¥681,550.40 for the quarter, an increase of 102.17% year-over-year [10]. - The company's net profit for the current period is 681,550.40, a significant recovery from a net loss of 31,362,520.12 in the previous period, indicating a turnaround in performance [38]. - The company reported a total comprehensive income of 12,361,717.16, a recovery from a loss of 39,475,973.22 in the previous period [39]. - The basic and diluted earnings per share are both reported at 0.00, recovering from -0.02 in the previous period [39]. Cash Flow - The net cash flow from operating activities improved to ¥4,058,191.55, a 102.55% increase from the previous year [8]. - The net cash flow from operating activities was 4,058,191.55 CNY, a significant improvement from a net outflow of 159,307,829.82 CNY in the previous period [46]. - Total cash inflow from operating activities amounted to 1,070,840,365.76 CNY, compared to 812,069,678.24 CNY last year, reflecting a year-over-year increase of approximately 32% [46]. - The ending cash and cash equivalents balance was 580,753,250.24 CNY, down from 877,420,594.35 CNY, reflecting a decrease of approximately 34% [47]. - The net cash flow from financing activities in the first quarter of 2025 was 107,957,430.36 CNY, a significant increase from 21,765,295.53 CNY in the previous year [50]. Assets and Liabilities - Total assets as of March 31, 2025, amounted to ¥11,857,819,091.96, a decrease of 0.41% compared to the end of 2024 [8]. - The company's asset-liability ratio (consolidated) was 57.41%, slightly down from 57.70% at the end of 2024 [8]. - The company's total liabilities as of March 31, 2025, amounted to CNY 6,808,041,753.95, compared to CNY 6,870,171,796.31 at the end of 2024, reflecting a reduction of approximately 0.90% [31]. - Current liabilities include short-term borrowings of 2,741,509,561.77 yuan, an increase from 2,612,915,817.81 yuan [28]. - The total current liabilities amounted to CNY 5,750,489,373.40 as of March 31, 2025, compared to CNY 5,847,023,608.43 at the end of 2024, indicating a decrease of about 1.65% [31]. Shareholder Information - The total number of ordinary shareholders was 24,528 as of the end of the reporting period [15]. - The company’s total equity attributable to shareholders increased by 0.31% to ¥5,059,958,705.69 compared to the end of 2024 [8]. - The largest shareholder, Huabang Life Health Co., Ltd., holds 569,438,458 shares, representing 46.45% of total shares [17]. - Zhejiang Xin'an Chemical Group Co., Ltd. is the second largest shareholder with 150,950,000 shares, accounting for 12.31% [17]. - A total of 822,372,577 shares, or 67.08%, are held by the top ten shareholders [17]. Investment Performance - Investment income surged by 241.57% to ¥4,521,605.02 due to improved profitability of joint ventures [10]. - Investment income rose to 505,467.45 from 2,060,399.53, indicating a decline in investment performance [42]. - Cash inflow from investment activities totaled 31,550,000.00 CNY, slightly down from 33,348,416.00 CNY last year [47]. - The company reported a cash inflow of 932,064,924.68 CNY from investment activities in the first quarter of 2025, compared to 588,596,380.00 CNY in the same period last year [50]. Operational Efficiency - The net cash flow from investing activities was -43,178,078.56 CNY, an improvement from -165,241,888.51 CNY in the previous year [47]. - Cash outflow for purchasing goods and services was 750,417,827.92 CNY, up from 681,430,474.77 CNY, indicating a rise of about 10% [46]. - Total operating costs for Q1 2025 were CNY 1,390,914,399.31, down from CNY 1,400,108,915.88 in Q1 2024, indicating a decrease of about 0.14% [37]. - Research and development expenses for Q1 2025 were CNY 39,977,073.76, slightly up from CNY 38,485,848.65 in Q1 2024, indicating an increase of about 3.89% [37]. Future Outlook - The company plans to focus on new product development and market expansion strategies to enhance future growth prospects [38].

Business Performance - The company's operating revenue for 2024 was approximately ¥5.83 billion, a decrease of 0.65% compared to ¥5.87 billion in 2023[28]. - The net profit attributable to shareholders was a loss of approximately ¥587.33 million, representing a decline of 713.83% from a profit of ¥95.68 million in 2023[28]. - The gross profit margin decreased to 10.44% in 2024 from 17.12% in 2023[28]. - Total assets decreased by 5.82% to approximately ¥11.91 billion in 2024, down from ¥12.64 billion in 2023[31]. - The company's debt-to-asset ratio increased to 57.70% in 2024 from 54.21% in 2023[31]. - Cash flow from operating activities significantly improved to approximately ¥249.89 million, a 553.70% increase from ¥38.23 million in 2023[31]. - The company reported a net profit growth rate of -753.67% for 2024, compared to -91.38% in 2023[31]. - The company's operating profit for 2024 was approximately -¥629 million, a decline of 477.21% compared to a profit of ¥167 million in 2023[67]. - The company's net profit for 2024 was approximately -¥596 million, a drastic decline of 753.67% compared to a profit of ¥91 million in 2023[68]. - The company achieved operating revenue of approximately ¥5.83 billion in the reporting period, a decrease of ¥38.42 million compared to the previous year[55]. Research and Development - The company’s self-developed herbicide-resistant cotton KJC017 and insect-resistant herbicide-resistant corn KJ1003 obtained national production application safety certificates in July 2024, indicating readiness for commercialization[6]. - Multiple products from the subsidiary Jiangxi Heyidu won the second prize in the Jiangxi Province Agricultural Science and Technology Award in the first half of 2024, showcasing the company's strength in pesticide R&D innovation[8]. - The company has established a mature independent innovation system with a focus on R&D, participating in multiple national and provincial key R&D projects[47]. - The company collaborates closely with clients during the R&D process to integrate their requirements into product development[41]. - The company’s R&D expenses rose by 4.14% to approximately ¥173 million, reflecting ongoing investment in innovation despite financial challenges[67]. - The total number of patents owned by the company increased to 391, with 216 being invention patents, up from 196 in the previous period[96]. Market Position and Recognition - In May 2024, the company ranked among the top ten in the national pesticide industry sales TOP100 list released by the China Pesticide Industry Association[5]. - In August 2024, the company was listed in the "2024 China Fine Chemical Top 100" and recognized as one of the "Top 20 Innovative Development Enterprises in China Fine Chemicals"[5]. - The company has 1,298 overseas pesticide registration certificates, including 213 self-registered, and 421 domestic pesticide registration certificates, with 157 for active ingredients, positioning it among the industry leaders[49]. - The company continues to serve major agrochemical firms, including ADAMA and SYNGENTA, with advanced technology and products[40]. Environmental and Social Responsibility - The company has implemented various social responsibility initiatives, including cash assistance for rural infrastructure and poverty alleviation, demonstrating its commitment to community support[108]. - The company has established a five-year EHS strategic plan for 2024-2029, focusing on environmental protection goals including waste emission intensity reduction[116]. - The company has committed to reducing carbon emissions in line with national "carbon peak" and "carbon neutrality" goals, promoting sustainable development[117]. - The company has created job opportunities for disadvantaged groups, including the poor and disabled, contributing to social employment[118]. - The company has received tax benefits related to the employment of disabled individuals, allowing for VAT refunds based on the number of disabled employees[91]. Financial Management and Risks - The company faces risks from improper control by major shareholders, with 卓远汇医投资有限公司 holding 47.70% of the shares, potentially impacting operational decisions[167]. - The company's revenue from international sales accounts for approximately 49.57%, making it vulnerable to changes in export tax rebate policies[168]. - The company is subject to a corporate income tax rate of 15% as a high-tech enterprise, which may be affected by changes in national tax policies[168]. - The company is experiencing structural overcapacity in the pesticide market, leading to continuous price declines and adverse effects on operations[171]. - The company is investing in environmental protection measures to comply with increasingly stringent regulations, which may increase operational costs[169]. Future Strategies - The company aims to focus on high-quality sustainable development, transitioning from scale expansion to sustainable growth, while optimizing product quality and core business[151]. - Plans for 2025 include cost reduction and efficiency improvement through lean management and operational streamlining to enhance production efficiency[154][155]. - The company will prioritize product competitiveness by eliminating underperforming products and focusing resources on developing high-value new materials and advanced chemical products[156][157]. - Marketing strategies will shift to target large clients and explore new markets in Southeast Asia, Africa, and Eastern Europe to expand business opportunities[158]. - The company will optimize asset utilization by revitalizing idle assets and improving debt structure to enhance financial efficiency[159][160]. Compliance and Governance - The company continues to adhere to regulatory compliance and governance standards, ensuring the protection of investor interests in accordance with relevant laws and regulations[111]. - The company ensures timely and accurate information disclosure to maintain investor relations and protect the rights of small and medium investors[112]. - The company has not reported any instances of shareholder or related party misappropriation of funds or assets during the reporting period[185]. - The company has no reported violations or irregularities regarding guarantees provided[184].

颖泰生物公告，2024年营业收入58.3亿元，同比下降0.65%。归属于上市公司股东的净利润亏损5.87亿 元，去年同期净利润9568.35万元。基本每股收益-0.48元/股。公司归属于上市公司股东的扣除非经常性 损益后的净利润亏损5.95亿元。 ...

颖泰生物公告，2025年一季度营业收入13.87亿元，同比增长0.96%。净利润234.84万元，同比增长 107.89%。 ...

证券代码：833819 证券简称：颖泰生物 公告编号：2025-005 北京颖泰嘉和生物科技股份有限公司关于 部分董事、高级管理人员自愿增持股份计划延期公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带法律责任。 北京颖泰嘉和生物科技股份有限公司（以下简称"公司"）于 2024 年 9 月 13 日在北京证券交易所指定信息披露平台披露了《关于部分 董事、高级管理人员增持股份计划公告》（公告编号：2024-040）。在 增持计划实施期间，因受公司定期报告敏感期及交易监管等多重因素 影响导致增持主体未能在原定期限内完成本次增持计划，本着诚实守 信、继续实施增持股份计划的原则，增持主体拟延长增持股份计划的 履行期限，即自原增持计划期满之日起延长 3 个月至 2025 年 6 月 13 日。除前述调整外，原增持计划其他内容保持不变。 具体情况见下： 一、 增持主体的基本情况 | 序号 | 姓名 | 职务 增持前持公司股份数量（股） | | --- | --- | --- | | 1 | 陈伯阳 | 董事长 0 | | ...

Financial Performance - The company's operating revenue for 2024 is expected to be ¥5,832,265,391.65, a decrease of 0.61% compared to the previous year[4] - The total profit for the period is projected to be -¥577,528,392.91, representing a decline of 453.84% year-over-year[4] - The net profit attributable to shareholders is expected to be -¥551,134,452.59, a decrease of 676.00% compared to the same period last year[4] - The net profit after deducting non-recurring gains and losses is projected to be -¥549,194,034.88, down 1,216.26% year-over-year[4] - The basic earnings per share is expected to be -¥0.45, a decline of 662.50% compared to the previous year[4] Assets and Equity - Total assets at the end of the reporting period are expected to be ¥11,947,971,106.93, a decrease of 5.49% from the beginning of the period[5] - Shareholders' equity is projected to be ¥5,069,345,743.79, down 12.37% from the beginning of the period[5] - The estimated net asset value per share attributable to shareholders is expected to be ¥4.14, a decrease of 12.29% from the beginning of the period[5] Market Conditions - The decline in performance is attributed to factors such as slowing customer demand and intensified market competition, leading to lower product prices and gross margins[6][7] - The company has recognized impairment provisions for certain asset groups due to ongoing price declines, significantly impacting net profit[7]